Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1245-1249

  Zareie, Mehri ^a   Brattsand, Ralph ^b   Sherman, Philip M ^c   McKay, Derek M ^a   Perdue, Mary H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Preclinical Research and Development   (Sweden)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; D 5519; FORSKOLIN; GLUCOCORTICOID; S 1316; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENTERITIS; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; ION TRANSPORT; MACROPHAGE ACTIVATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

BUDESONIDE; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; COLON; EPITHELIAL CELLS; GLUCOCORTICOIDS; HUMANS; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MACROPHAGES; MEMBRANE POTENTIALS; SALMONELLA;

EID: 0032993619     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Baldassano RN, Schreiber S, Johnston RB, Fu RD, Muraki T and MacDermott RP (1993) Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology 105:60-66.
2. Brattsand R (1990) Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Con J Gastroenterol 4:407-414.
3. Brogden RN, McTavish D, Barnes PJ, Gross NJ, Juniper E and Laursen LC (1992) Budesonide: An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 44:375-407.
4. Campieri M, Ferguson A, Doe W, Persson T, Nilsson L and The Global Budesonide Study Group (1997) Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 41:209-214.
5. Cui N, Friend DR and Fedorak RN (1994) A budesonide prodrug accelerates treatment of colitis in rats. Gut 35:1439-1446.
6. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L and Persson T (1994) Oral budesonide for active Crohn's disease. N Engl J Med 331:836-841.
7. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L, Persson T and The Canadian Inflammatory Bowel Disease Study Group (1996) Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 110:45-51.
8. Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P and Doe WF (1995) Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 10:387-395.
9. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, Rasenack J, Weber A, Gierend M, Ewe K, Scholmerich J and The Budesonide Study Group (1998) Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. Gut 42:493-496, 1998.
10. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson L, Walton-Bowen K, Haskell LP and Levine JG (1998) Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose ranging study. Gastroenterology 115:525-532.
11. Linden M and Brattsand R (1994) Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: Differential sensitivity of GM-CSF, IL-1β and IL-6. Pulmonary Pharmacol 7:43-47.
12. Lofberg R, Danielsson A and Salde L (1993) Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 7:611-616.
13. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R and Persson T (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110:1713-1718.
14. Madara JL, Patapoff TW, Gillece-Castro B, Colgan SP, Parkos CA, Delp-Archer C and Mrsny RJ (1993) 5′-Adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest 91:2320-2325.
15. Madara JL and Stafford J (1989) Interferon-gama directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83:724-727.
16. McKay DM, Brattsand R, Wieslander E, Fung M, Croitoru K and Perdue MH (1996a) Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. J Pharmacol Exp Therapeut 277:403-410.
17. McKay DM, Croitoru K and Perdue MH (1996b) T cell-monocyte interactions regulate epithelial physiology in a coculture model of inflammation. Am J Physiol 270:C418-C428.
18. Oddera S, Silvestri M, Sacco O, Lantero S, Morelli MC and Rossi G (1995) Evaluation of the inhibitory effects of budesonide on the mitogen-induced or the allergeninduced activation of blood mononuclear cells isolated from asthmatic patients. Ann Allergy Asthma Immunol 75:33-40.
19. Pederson S and O'Byrne P (1997) A comparison of the efficacy and safety of inhaled corticosteroid in asthma. Eur J Allergy Clin Immunol 52:1-34.
20. Perdue MH and McKay DM (1994) Integrative immunophysiology in the intestinal mucosa. Am J Physiol 267:G151-G165.
21. Powell DW (1981) Barrier function of epithelia. Am J Physiol 241:G275-G288.
22. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O and Scott H (1994) Increased macrophage subset in inflammatory bowel disease: Apparent recruitment from peripheral blood monocytes. Gut 35:669-674.
23. Rutgeerts P, Loefberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Ostergard Thompsen O, Lorenz-Meyer H, Hodgson H, Persson T and Seidegaard C (1994) A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842-845.
24. Thalén BA, Halen BA, Axelsson BL, Andersson PH, Brattsand RL, Nylander B and Wickstorm L (1998) 6α-Fluoro- and 6α,9α-difluoro-11β,21-dihydroxy-16α,17α- propylmethylene-dioxypregn-4-ene-3,20-dione: Synthesis and evaluation of activity and kinetics of their C-22 epimers. Steroids 63:37-43.
25. Waage A and Bakke (1988) Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 63: 299-302.
26. Zareie M, McKay DM, Kovarik GG and Perdue MH (1998) Monocyte/macrophages evoke epithelial dysfunction: Indirect role of tumor necrosis factor-α. Am J Physiol 275:C932-C939.